<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178306</url>
  </required_header>
  <id_info>
    <org_study_id>502.339</org_study_id>
    <nct_id>NCT02178306</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis</brief_title>
  <acronym>ESPRIT</acronym>
  <official_title>An Open-labeled, Placebo run-in, Multicentre Study to Investigate the Efficacy and Safety of Telmisartan (40 and 80 mg QD p.o.) in 3 Strata of Mild to Moderate Hypertensive Patients (Sitting Diastolic Blood Pressure ≥ 90 mmHg and ≤ 109 mmHg From Office Cuff Measurement) With Mild/Moderate or Severe Renal Impairment or Requiring Maintenance Hemodialysis. (ESPRIT Study = Efficacy and Safety in Patients With Renal Impairment Treated With Telmisartan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy, in particular with regard to renal function of&#xD;
      telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to&#xD;
      endstage renal impairment after 12 weeks of treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in seated diastolic blood pressure (DBP) at trough</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in seated systolic blood pressure (SBP) at trough</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of response categories of blood pressure</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Categories:&#xD;
BP normal&#xD;
DBP control&#xD;
DBP response&#xD;
SBP response&#xD;
BP high normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in proteinuria</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in electrolyte excretion</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the telmisartan plasma concentration-time curve</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of telmisartan</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak (Tmax) plasma concentrations of telmisartan</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of protein binding of telmisartan</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
    <description>equilibrium dialysis with subsequent determination of protein-bound telmisartan fraction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan low dose</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan high dose</intervention_name>
    <description>patients switch to high dose if mean SBP &gt;= 85 mmHg after 4 weeks of treatment</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Run-in phase</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mild to moderate hypertension, sitting diastolic BP ≥ 90 mmHg and BP ≤ 109 mmHg at&#xD;
             visit 2&#xD;
&#xD;
          2. No increase of serum creatinine over 30% within 6 months before the trial&#xD;
&#xD;
          3. Stable renal insufficiency with a serum creatinine between 200 and 600 µmol/l or&#xD;
             maintenance of hemodialysis&#xD;
&#xD;
          4. Stable proteinuria of at least 500 mg/24h&#xD;
&#xD;
          5. No change in hemodialysis regimen within the last two months prior to visit 1&#xD;
&#xD;
          6. 18 years of age or more&#xD;
&#xD;
          7. Ability to provide written informed consent in accordance with good clinical practice&#xD;
             and local registration&#xD;
&#xD;
          8. Able to stop current antihypertensive therapy (ACE-Inhibitors or angiotensin II&#xD;
             receptor subtype 1- Blocker) without risk to the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in-phase) who:&#xD;
&#xD;
               1. are not surgically sterile; and/or&#xD;
&#xD;
               2. are nursing&#xD;
&#xD;
               3. are of child-bearing potential and are NOT practicing acceptable means of birth&#xD;
                  control, do NOT plan to continue using this method throughout the study and do&#xD;
                  NOT agree to submit to periodic pregnancy testing during participation in studies&#xD;
                  of ≥ 3-months duration. Acceptable methods of birth control include oral,&#xD;
                  implantable or injectable contraceptives&#xD;
&#xD;
          2. Known or suspected renovascular hypertension&#xD;
&#xD;
          3. Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥110 mmHg during any visit of the&#xD;
             placebo run-in phase&#xD;
&#xD;
          4. Hepatic dysfunction as defined by the following laboratory parameters:&#xD;
&#xD;
             serum glutamate pyruvate transaminase (ALT) or serum glutamate oxaloacetate&#xD;
             transaminase (AST) &gt; than 2 times the upper limit of normal range&#xD;
&#xD;
          5. Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients&#xD;
             postrenal transplant or with only one kidney&#xD;
&#xD;
          6. Clinically relevant hypo- or hyperkalaemia&#xD;
&#xD;
          7. Uncorrected volume depletion&#xD;
&#xD;
          8. Uncorrected sodium depletion&#xD;
&#xD;
          9. Primary aldosteronism&#xD;
&#xD;
         10. Hereditary fructose intolerance&#xD;
&#xD;
         11. Biliary obstructive disorders&#xD;
&#xD;
         12. Patients who have previously experienced symptoms characteristic of angioedema during&#xD;
             treatment with ACE inhibitors or angiotensin II antagonists&#xD;
&#xD;
         13. History of drug or alcohol abuse within 6 months&#xD;
&#xD;
         14. Chronic administration of any medications known to affect blood pressure, except&#xD;
             medication allowed by the protocol (ß-blocker, alpha-blocker, calcium antagonists,&#xD;
             clonidine, minoxidil, and diuretics)&#xD;
&#xD;
         15. Any investigational therapy within one month of signing the informed consent form&#xD;
&#xD;
         16. Known hypersensitivity to any component of the formulation&#xD;
&#xD;
         17. Has no contra-indication to a placebo run-in period (e.g. unstable angina within the&#xD;
             past 3 months, stroke within the past 6 months or myocardial infarction or cardiac&#xD;
             surgery within the past 3 months)&#xD;
&#xD;
         18. Any other clinical condition which, in the opinion of the investigator, would not&#xD;
             allow safe completion of the protocol and safe administration of telmisartan&#xD;
&#xD;
         19. Compliance &lt; 70% during run-in period (defined by pill count)&#xD;
&#xD;
         20. History of heart failure, malignancy, or any disorders requiring immunosuppressive&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.339.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.339_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

